Total Payments
$129,868
2024 Payments
$29,162
Companies
15
Transactions
191
Medicare Patients
317
Medicare Billing
$39,997
Payment Breakdown by Category
Research$53,890 (41.5%)
Consulting$40,780 (31.4%)
Other$29,915 (23.0%)
Food & Beverage$3,398 (2.6%)
Travel$1,499 (1.2%)
Education$386.06 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53,890 | 51 | 41.5% |
| Consulting Fee | $40,780 | 19 | 31.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,405 | 26 | 19.6% |
| Honoraria | $4,510 | 3 | 3.5% |
| Food and Beverage | $3,398 | 48 | 2.6% |
| Travel and Lodging | $1,499 | 5 | 1.2% |
| Education | $386.06 | 39 | 0.3% |
Payments by Type
General
$75,978
140 transactions
Research
$53,890
51 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $63,854 | 99 | $0 (2024) |
| F. Hoffmann-La Roche AG | $18,664 | 14 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $16,957 | 26 | $0 (2024) |
| GlaxoSmithKline, LLC. | $10,617 | 11 | $0 (2020) |
| PUMA BIOTECHNOLOGY, INC. | $4,676 | 11 | $0 (2024) |
| AstraZeneca UK Limited | $3,425 | 1 | $0 (2021) |
| Gilead Sciences, Inc. | $3,000 | 6 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $2,254 | 2 | $0 (2024) |
| BeiGene USA, Inc. | $2,250 | 2 | $0 (2024) |
| Immunomedics, Inc. | $1,375 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,162 | 25 | PFIZER INC. ($19,070) |
| 2023 | $14,531 | 19 | PFIZER INC. ($9,324) |
| 2022 | $17,065 | 25 | PFIZER INC. ($9,500) |
| 2021 | $15,206 | 19 | PFIZER INC. ($8,570) |
| 2020 | $17,037 | 15 | Novartis Pharmaceuticals Corporation ($7,678) |
| 2019 | $10,840 | 28 | PFIZER INC. ($5,191) |
| 2018 | $14,845 | 31 | GlaxoSmithKline, LLC. ($6,617) |
| 2017 | $11,183 | 29 | PFIZER INC. ($6,557) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $125.79 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $48.09 | General |
| Category: Oncology | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $46.22 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $35.99 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $61.77 | General |
| Category: Oncology | ||||||
| 09/13/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 08/13/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Oncology | ||||||
| 08/06/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/31/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Oncology | ||||||
| 07/18/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/18/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 06/01/2024 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $214.18 | General |
| 05/16/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 03/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | — | Cash or cash equivalent | $4,716.48 | Research |
| Study: CLEE011A2301,CLEE011E2301-MONALEESA-7,CLEE011F2301 • Category: Oncology | ||||||
| 03/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $40.19 | General |
| 03/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $130.80 | General |
| 02/12/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $79.77 | General |
| 02/06/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 01/31/2024 | JAZZ PHARMACEUTICALS INC. | — | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| 01/16/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 01/16/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $40,930 | 40 |
| CLEE011A2301,CLEE011E2301-MONALEESA-7,CLEE011F2301 | Novartis Pharmaceuticals Corporation | $4,716 | 1 |
| IBRANCE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,803 | 4 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $958.51 | 2 |
| AN OBSERVATIONAL COHORT STUDY OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2 POSITIVE HER2 METASTATIC BREAST CANCER SYSTHERS REGISTRY SYSTEMATIC THERAPIES FOR HER2 METASTATIC BREAST CANCER STUDY | F. Hoffmann-La Roche AG | $824.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $458.40 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 73 | 133 | $31,251 | $8,518 |
| 2022 | 2 | 81 | 158 | $36,342 | $10,514 |
| 2021 | 4 | 101 | 204 | $50,527 | $15,309 |
| 2020 | 2 | 62 | 122 | $22,210 | $5,656 |
Total Patients
317
Total Services
617
Medicare Billing
$39,997
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 42 | 90 | $23,900 | $6,547 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 31 | 43 | $7,351 | $1,972 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 50 | 116 | $29,468 | $8,578 | 29.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 31 | 42 | $6,874 | $1,937 | 28.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 93 | $22,839 | $7,291 | 31.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 29 | 62 | $9,768 | $2,939 | 30.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 32 | $9,056 | $2,633 | 29.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $8,864 | $2,446 | 27.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 38 | 78 | $11,850 | $3,012 | 25.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 24 | 44 | $10,360 | $2,644 | 25.5% |
About Dr. Debasish Tripathy, M.D
Dr. Debasish Tripathy, M.D is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194794602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Debasish Tripathy, M.D has received a total of $129,868 in payments from pharmaceutical and medical device companies, with $29,162 received in 2024. These payments were reported across 191 transactions from 15 companies. The most common payment nature is "" ($53,890).
As a Medicare-enrolled provider, Tripathy has provided services to 317 Medicare beneficiaries, totaling 617 services with total Medicare billing of $39,997. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Houston, TX
- Active Since 03/16/2006
- Last Updated 05/06/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1194794602
Products in Payments
- IBRANCE (Drug) $41,493
- Herceptin (Biological) $15,364
- KISQALI (Drug) $11,141
- PIQRAY (Drug) $4,888
- NERLYNX (Drug) $2,563
- TRODELVY (Drug) $1,375
- BYL719H (Drug) $738.00
- Trodelvy (Drug) $708.25
- ENHERTU (Biological) $272.00
- Non-Covered Product (Drug) $145.37
- Nerlynx (Drug) $75.67
- IGT_D Systems (Device) $39.23
- LYNPARZA (Drug) $21.70
- TECENTRIQ (Biological) $19.67
- TALZENNA (Drug) $11.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001